Valuation: Shield Therapeutics plc

Market Cap 66.24M 89.12M 77.88M 71.87M 125M 8.58B 128M 859M 338M 4.2B 335M 327M 14.47B P/E 2026 *
-282x
P/E 2027 * 8.4x
Enterprise Value 84.29M 113M 99.1M 91.45M 159M 10.92B 162M 1.09B 430M 5.35B 426M 417M 18.41B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.03x
Free-Float
38.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week-3.12%
1 month-3.12%
3 months-33.69%
6 months-49.18%
Current year-37.06%
1 week 6
Extreme 6
6.5
1 month 5.8
Extreme 5.8
6.7
Current year 5.7
Extreme 5.7
12.5
1 year 3.4
Extreme 3.4
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
53
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Investor Relations Contact - -
General Counsel - 01/01/2026
Director TitleAgeSince
Chairman 70 18/06/2020
Director/Board Member 68 01/02/2016
Director/Board Member 59 10/05/2021
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/2/25 Buy

Chief Executive Officer

575,000 0.0552%
13/2/25 Free

Chief Executive Officer

5,000,000 0.4800%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-3.12%+74.65%-3.12% 89.12M
-0.33%+1.83%+24.73%-6.86% 68.85B
+0.67%+0.93%+36.86%+197.49% 52.13B
+0.94%+39.60%+39.60%+39.60% 43.46B
+1.12%+0.35%-52.09%-53.39% 41.24B
-1.40%+3.43%+64.81%-25.41% 30.41B
-2.11%-9.45%+97.76%-49.58% 24.53B
+0.51%+0.46%+72.78%+90.09% 23.42B
-5.57%-0.84%-0.11%+182.38% 19.75B
-0.86%-1.99%+70.03%+117.01% 16.57B
Average -0.78%-1.04%+42.90%+48.82% 32.04B
Weighted average by Cap. -0.34%-0.07%+32.57%+46.82%

Financials

2026 *2027 *
Net sales 55.68M 74.9M 65.46M 60.4M 105M 7.21B 107M 722M 284M 3.53B 281M 275M 12.16B 75.12M 101M 88.32M 81.49M 142M 9.73B 145M 974M 383M 4.77B 380M 371M 16.41B
Net income -74.5K -100K -87.59K -80.82K -140K -9.65M -144K -966K -380K -4.73M -376K -368K -16.27M 7.86M 10.57M 9.24M 8.53M 14.82M 1.02B 15.14M 102M 40.09M 499M 39.71M 38.84M 1.72B
Net Debt 18.05M 24.28M 21.22M 19.58M 34.02M 2.34B 34.78M 234M 92.06M 1.15B 91.19M 89.19M 3.94B 10.95M 14.73M 12.87M 11.88M 20.64M 1.42B 21.1M 142M 55.85M 695M 55.32M 54.11M 2.39B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
17/07/26 GBX 6.200 -0.80% 575,604
16/07/26 GBX 6.250 0.00% 49,905
15/07/26 GBX 6.250 0.00% 100,521
14/07/26 GBX 6.250 0.00% 390,933
13/07/26 GBX 6.250 -2.34% 2,057,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0620GBP
Average target price
0.1667GBP
Spread / Average Target
+168.82%

Annual profits - Rate of surprise